Overview of Paramol

Property	Description
Active Ingredients	Paracetamol (Acetaminophen), Dihydrocodeine tartrate
Form	Tablet
Pharmacological Class	Fixed-dose combination analgesic, Anti-pyretic
Common Use	Acute moderate pain relief
Origin	Synthetic (Semi-synthetic opioid derivative)

Paramol is the trade name for a specific fixed-dose combination analgesic, generically known as Co-dydramol, which is designed for oral administration. It is fundamentally classified as an analgesic and anti-pyretic due to its two-pronged action in reducing pain and lowering an elevated body temperature. Its identity as a combination product distinguishes it from single-ingredient medicines, allowing it to provide a stronger effect for pain management. Co-dydramol is a combination painkiller used when paracetamol alone is not sufficient. This indicates that the medicine is positioned for use in cases of breakthrough or persistent discomfort.

What Type of Analgesic is Paramol (Co-dydramol)?

Paramol belongs to the class of combination painkillers, merging a non-opioid analgesic (Paracetamol) with an opioid analgesic (Dihydrocodeine tartrate) in a single tablet. This dual pharmacological class mechanism is utilized for the short-term treatment of acute moderate pain. This approach is intended to provide greater efficacy in managing specific types of discomfort compared to the non-opioid component alone. Other products containing this same combination, such as Remedeine, share this foundation.

Composition: Paracetamol, Dihydrocodeine, and Origin

The core composition consists of Paracetamol (Acetaminophen) and Dihydrocodeine tartrate, both of which are synthetic compounds; dihydrocodeine is classified as a semi-synthetic opioid derivative. The inclusion of an opioid component is designed to enhance the overall analgesic effect. This composition facilitates a Dual Pain Blockade, where paracetamol works to inhibit chemical messengers that cause pain, and dihydrocodeine modifies the perception of pain signals within the central nervous system.

Regulatory References

FDA-approved label for Acetaminophen, Caffeine, and Dihydrocodeine

What side effects are possible with Paramol?

Possible Side Effects and Safety Information

The safety profile of Paramol, which combines Paracetamol and Dihydrocodeine, is strictly defined by regulatory documents, reflecting the common effects of both components and high-level safety warnings. Adverse reactions are classified according to official frequency standards.

Frequency-Classified Adverse Reactions

Frequency	Common Effects	System-Organ Classes
Very Common	Nausea, Vomiting	Gastrointestinal Disorders
Common	Constipation, Dizziness, Sedation, Headache	Gastrointestinal, Nervous System Disorders

Less frequently, the label documents effects across other systems, including rare manifestations such as certain Blood and Lymphatic System Disorders (e.g., thrombocytopenia) and Hypersensitivity Reactions within the Immune System Disorders class. These classifications reflect the categories used by official regulatory authorities.

Serious Adverse Reactions and Safety Constraints

Regulatory information prominently highlights serious safety concerns. The potential for Hepatotoxicity (liver damage) is a primary risk associated with the Paracetamol component, particularly concerning high cumulative doses. The Dihydrocodeine component carries the risk of Respiratory Depression and is associated with the development of Drug Dependence and Tolerance.

Due to these risks, regulatory texts impose safety-related restrictions, notably limiting the use of this combination to short-term treatment only. Additionally, special safety notes apply to certain populations: individuals with Severe Hepatic Impairment face an increased risk of toxicity, and older patients may experience increased susceptibility to the medicine's sedative effects.

Overdose and Emergency Response

The official regulatory profile for this fixed-dose combination requires immediate action in the event of a suspected overdose due to the potential for severe, delayed toxicity from its active ingredients.

Documented Clinical Manifestations and Outcomes

Paracetamol Component: Initial symptoms may be limited to nausea, vomiting, pallor, and abdominal pain within the first 24 hours. The latency of toxicity means severe outcomes like hepatic necrosis, hepatic failure, and acute renal failure may develop 12 to 48 hours later. Overdose hazards are greater in patients with alcoholic liver disease or malnutrition.
Dihydrocodeine Component: Toxicity from the opioid component primarily involves central nervous system depression, including somnolence and confusion. A life-threatening risk is fatal respiratory depression, which is a particular concern in children following accidental ingestion.

Mandatory Emergency Actions

Action	Regulatory Requirement
Immediate Advice	Immediate medical advice must be sought, even if the patient currently presents with no symptoms.
Urgent Transfer	Patients should be referred to hospital urgently or transferred immediately to a specialised unit for continuous monitoring and management.

Officially Described Management

Management procedures include the immediate institution of the antidote N-acetylcysteine to prevent liver injury from Paracetamol. For the opioid component, treatment focuses on supportive measures to maintain respiratory and circulatory functions. Hospital monitoring involves testing plasma paracetamol concentration at four hours or later post-ingestion, along with regular hepatic and renal function tests.

Therapeutic Uses of Paramol

What Paramol Treats: Main Uses and Benefits

Enhanced Symptom Relief for Moderate Acute Pain

Paramol is commonly used in situations involving certain distressing symptoms where the intensity of moderate pain is deemed insufficiently addressed by non-opioid analgesics. The combination is applied across domains where additional symptomatic support is needed, such as musculoskeletal aches, dental discomfort, and painful acute episodes like headaches or migraines, which provides support that helps ease the overall symptom burden.

The medication is typically utilized in contexts marked by increased discomfort or tension, helping to address symptom clusters that may become intense or disruptive. Common indications include pain from toothache, period pain, muscle pain, and joint pain. It is applied in addressing pronounced pain manifestations and generally plays a role in managing an elevated body temperature (fever), which may assist with maintaining comfort during periods of heightened symptoms.

Supportive Analgesia in Short-Term Clinical Scenarios

Paramol is commonly used across conditions presenting with acute episodes, such as post-operative pain in the acute recovery phase or discomfort following minor injuries. It provides short-term symptomatic assistance relevant when symptoms create noticeable functional strain, helping patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Moderate Pain Paramol is intended for use when pain severity is moderate and temporary, providing supportive relief when single-ingredient paracetamol is insufficient to help manage symptoms that interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Paramol? (Co-dydramol)

The official regulatory profile for Paramol strictly defines eligibility based on age, physiological status, and underlying health conditions, as documented by authorities like the EMA and FDA. This medicine is primarily intended for use by adults and adolescents aged 12 years and over.

Absolute Contraindications

Use is formally contraindicated in specific populations to prevent serious risks:

Children under 12 years of age.
Women who are breastfeeding.
Patients known to be CYP2D6 ultra-rapid metabolisers.
Children (0–18 years) who have undergone tonsillectomy or adenoidectomy for Obstructive Sleep Apnoea Syndrome (OSAS).
Individuals with severe liver disease, respiratory depression, COPD, or known hypersensitivity to Paracetamol or Dihydrocodeine.

Conditional Use and Restrictions

Regulatory documents mandate caution and potential dosage adjustment for certain groups:

Elderly patients and individuals with impaired renal or hepatic function (excluding severe disease).
Patients with a history of substance misuse disorder or raised intracranial pressure.
Pregnancy: Use is conditional and should be limited to situations where it is clinically necessary, due to the risk of neonatal withdrawal syndrome.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Paramol is structured by the effects of its two active components, Paracetamol and Dihydrocodeine. Co-administration with other products containing either substance is strictly prohibited.

Classification	Interacting Substance/Class	Documented Constraint
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited co-administration; a two-week washout period is mandatory after stopping MAOIs due to the risk of severe CNS excitation.
Prohibited	Any other Paracetamol or Codeine/opioid product	Prohibited to avoid the documented risk of overdose and additive severe opioid-related adverse effects.

The interaction with Sedative Medicines and CNS Depressants (including alcohol, hypnotics, and tricyclic antidepressants) results in a formally documented additive CNS depressant effect. This same risk applies to Anticholinergics and Antidiarrhoeal agents, which increase the risk of severe constipation.

Exposure-modifying substances are also documented: Cimetidine inhibits opioid metabolism, resulting in increased Dihydrocodeine plasma concentration. The speed of Paracetamol absorption is increased by Metoclopramide or Domperidone and reduced by Cholestyramine. Prolonged, regular use of the Paracetamol component is officially documented to enhance the anticoagulant effect of Warfarin. Furthermore, the hazard of Paracetamol overdose is greater in those with non-cirrhotic alcoholic liver disease.

Mechanism of Action

Dual Modulation of Nociceptive Pathways

This combination medicine exerts its effect through a complementary Dual Modulation targeting the Central Nervous System (CNS). The Dihydrocodeine component acts as an agonist at the mu-opioid receptor, directly attenuating the flow of ascending nociceptive signals and modulating supraspinal signal processing. Simultaneously, the Paracetamol component engages multiple non-opioid central pathways, resulting in an enhanced modulation by targeting both the chemical environment and the neuronal flow of nociceptive information.

Central Enzyme Modulation and Endogenous Pathway Influence

The Paracetamol mechanism involves complex action on enzyme systems. It acts as a reversible inhibitor of Central Cyclooxygenase (COX), limiting the synthesis of Prostaglandin E2 ( PGE2) in the hypothalamus. This disruption of PGE2 synthesis is essential for resetting an elevated thermal set-point to a lower physiological baseline. Furthermore, a metabolite of Paracetamol indirectly elevates the concentration of endogenous pain-regulating ligands by inhibiting the Fatty Acid Amide Hydrolase (FAAH) enzyme, thereby influencing the function of the endogenous endocannabinoid system.

Mechanistic Constraints: Metabolic Dependency

The maximum pharmacological effect of the opioid component's mechanism is physiologically constrained, as Dihydrocodeine is a prodrug that must be converted by the CYP2D6 enzyme into the more potent active metabolite, Dihydromorphine. Variability in an individual's CYP2D6 activity directly affects the concentration of this active metabolite, thereby influencing the degree of mu-opioid receptor engagement and the consequent physiological changes.

Dosage and Administration Information

Official Administration Guidelines

Paramol (Co-dydramol) is a fixed-dose combination analgesic intended exclusively for oral administration as a tablet. Its usage is defined by time-based constraints and dosage limits established by regulatory labels. The medicine can be taken with or without food and should be swallowed whole with a drink of water.

Standard Dosing Regimens and Frequency

Standard labeled instructions for adults (16 years and over) involve taking one to two tablets per dose. Dosing is scheduled on an as-needed basis (p.r.n.), with the frequency restricted to every four to six hours. A core procedural constraint is the absolute minimum interval: a period of at least four hours must elapse between any two consecutive doses to prevent accumulation of the active ingredients. The maximum amount allowed in any 24-hour period for adults is eight tablets, a limit primarily governed by the Paracetamol component. It is an administrative rule that no other product containing paracetamol can be consumed concurrently with Paramol.

Population and Duration Rules

Administration guidelines for pediatric patients differ: the medicine is not recommended for children under the age of 12. For adolescents aged 12 to 15 years, the labeled dose is one tablet every four to six hours, with the maximum daily intake restricted to four tablets. Furthermore, use is designated for short-term treatment only. For non-prescription access, this period should not exceed three days. If the medicine has been used for a prolonged duration, standard clinical protocols suggest implementing a plan for gradual dose reduction (tapering) when stopping treatment. Specific dose adjustments may be required for older adults or individuals with existing renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Paramol

Research Evidence for Acute Moderate Pain Relief

The foundational research for the Paramol combination analgesic, generically known as Co-dydramol, relies heavily on short-term Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies were used in research exploring how outcomes related to physical discomfort change over time. The primary research approach monitored patient-reported outcomes describing perceived discomfort in adults who were experiencing short-lived, moderate pain. Research examined how symptom intensity or variability evolved in observed populations during the study period.

Studies focused on the immediate period after a single dose, typically up to six hours, and generally for short courses of treatment lasting up to one week. Findings describe patterns observed in the studies related to the change in pain scores and the need for other types of pain relief. The evidence contributes to the broader evidence landscape for this fixed-dose combination, which is relevant in trials assessing short-term or episodic symptom patterns.

Studies Comparing Paramol to Placebo and Single Ingredients

These studies frequently compared the Paramol combination against an inactive treatment (placebo) and against the single ingredient, paracetamol, alone. Studies monitored outcomes reflecting daily functioning or activity level in the observed groups. Findings describe patterns related to patient-reported experience when taking the combination versus the other study arms. Research does not determine whether an individual will respond similarly to the group patterns observed in these comparative trials.

Evidence for Short-Term Pain Following Minor Procedures

Research on Acute Musculoskeletal Aches and Headaches

The combination medicine was evaluated in specialized clinical trials exploring its application for short-term pain after minor procedures. The evidence is derived from standardized research settings, such as studies conducted following dental extraction surgery in generally healthy adults. The research explores short-term symptom changes in conditions associated with acute or disruptive episodes.

Paramol was also studied for conditions characterized by fluctuating or episodic manifestations, such as acute flares of musculoskeletal discomfort and some types of headache or migraine. Findings were mixed across studies, potentially due to the heterogeneity in patient populations and the variety of conditions studied.

Gaps in Research and Areas of Uncertainty

Research highlights that the evidence is overwhelmingly short-term. This indicates that the long-term patterns of use beyond seven days are not fully established. There is limited information for long-term outcomes or durability of effect. Data for certain groups, such as older adults with multiple co-existing health conditions, remain insufficient, and subgroup findings are uncertain.

Frequently Asked Questions (FAQ)

Common questions about Paramol (FAQ)

Q: Is Paramol considered an over-the-counter medicine?

The status of Paramol (Co-dydramol) varies depending on the country and the strength of the medicine. Formulations that contain lower amounts of the opioid component may be available for purchase at a pharmacy without a prescription. However, regulatory documents state that formulations with higher strengths are generally designated as Prescription Only Medicine (POM).

Q: Why is Paramol sometimes prescribed by a doctor?

Regulatory information indicates that Paramol is intended for the relief of mild to moderate pain. Strengths that contain higher amounts of the opioid component (dihydrocodeine) are generally classified as Prescription Only Medicine (POM). Regulatory classification requires a prescription for these strengths.

Q: Is Paramol the same type of medicine as NSAIDs?

No, Paramol is not the same class of medicine as NSAIDs (Nonsteroidal Anti-inflammatory Drugs). According to official classification, Paramol is a fixed-dose combination analgesic containing a non-opioid component (Paracetamol) and an opioid component (Dihydrocodeine). NSAIDs are a separate drug class that works through different mechanisms.

Q: What should someone watch out for after starting Paramol?

Official patient safety information describes conditions where urgent medical attention is required, such as difficulty breathing, swelling of the throat, or a severe skin rash. It is noted that common side effects, as described in regulatory documents, include expected effects like dizziness and sedation (sleepiness).

Q: Does Paramol affect blood pressure readings?

Official caution lists indicate that extra care may be needed when Paramol is used by individuals with existing Hypotension (low blood pressure). This is addressed further in the official documents concerning eligibility and contraindications.

Q: Are there certain supplements that should be avoided when using Paramol?

Official patient information states that there is not enough information to confirm whether complementary medicines or supplements are safe to take with Paramol. This is because these products are generally not tested for their interaction effects with licensed medicines. Official guidance describes the importance of disclosing all such products to a healthcare provider.

Q: Is it necessary to wait a certain time before taking other medicines after Paramol?

Official administration guidelines mandate a core procedural constraint for the medicine itself: an interval of at least four hours must elapse between any two consecutive doses of Paramol (Co-dydramol). This rule is in place to prevent the accumulation of the active ingredients, particularly the paracetamol component.

Q: Can Paramol interact with certain herbal remedies?

Similar to other supplements, official patient information states that there is not enough information to confirm that herbal remedies are safe to take with Paramol. These products are generally not subjected to the required interaction testing. Therefore, official documents describe the need for caution.

Q: How quickly does Paramol generally start working after it is taken?

Based on official pharmacokinetic data, the onset of action for the Paracetamol component after oral administration is often cited at around 37 minutes. The active metabolite associated with the opioid component typically reaches its maximum concentration in the blood around 60 minutes after the medicine is taken.

Q: Is it possible for Paramol to stop working over time?

Yes, official safety and pharmacological reviews note that the opioid component of Paramol is associated with the risk of developing tolerance. Tolerance is a condition where the body gradually adapts to the medicine, and the original dose may become less effective for pain relief over time.

Q: What is the purpose of the different strengths of Paramol available?

Official product information indicates that while the Paracetamol component strength is standardized, Paramol (Co-dydramol) is available in different strengths of the Dihydrocodeine (opioid) component. The intent of having varying strengths is to allow healthcare professionals to select the appropriate option based on the severity of the pain being managed.

Q: Does Paramol carry a warning for people with asthma?

Official patient information describes that Paramol is to be used with caution for individuals with lung problems, including asthma or other breathing difficulties. This is primarily due to the opioid component, which carries a risk of Respiratory Depression, which is noted for patients with compromised respiratory function.

Q: Are there limitations on Paramol use for people who have had stomach ulcers?

While official contraindications are specific, certain clinical reviews and literature associated with the medicine note potential risks such as peptic ulcer and gastrointestinal (GI) bleeding. This evidence describes the conditions that may warrant caution or close supervision when the medicine is used.

Q: What is the half-life of Paramol described as in official information?

Official pharmacokinetic data describes the elimination rate of the active ingredients separately. The Paracetamol component has a plasma half-life of approximately 1.5 to 2.5 hours. The active metabolite of the opioid component has a half-life of about 3 hours.

Q: What is the difference between how Paramol works and how opioids work?

Paramol works through a dual mechanism. The Paracetamol component acts on non-opioid central pathways, while the Dihydrocodeine component is classified as an opioid agonist. This opioid acts on the mu-opioid receptors in the central nervous system, which is the primary method by which opioids reduce the perception of pain signals.

How should Paramol be stored and disposed of?

Storage and Disposal of Paramol (Co-dydramol)

Official regulatory labeling dictates strict conditions for storing Paramol tablets to maintain stability and prevent accidental ingestion.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store below 25°C.
Protection	Keep the blister in the original package to protect from light.
Safety	Keep out of the sight and reach of children.
Stability	Do not use this medicine after the expiry date.

Disposal Instructions

Unused or expired Paramol must not be disposed of in household waste or wastewater. The official instruction is to consult a pharmacist on how to discard medicines you no longer use, ensuring proper pharmaceutical waste handling. Due to its opioid component, US guidance may recommend immediate flushing if a drug take-back option is unavailable.

Paramol